etybenzatropine

Etybenzatropine
Systematic (IUPAC) name
	(1R,5R)-3-(dicyclohexylmethoxy)-8-ethyl-; 8-azabicyclo[3.2.1]octane
Clinical data
Pregnancy cat.	?
Legal status	?
Routes	Oral, IM, IV
Identifiers
CAS number	524-83-4
ATC code	N04AC30
PubChem	CID 71637
ChemSpider	16736129
UNII	G1X2X9N95N
KEGG	D04087
Chemical data
Formula	C22H27NO
Mol. mass	321.456 g/mol
	SMILES CCN4[C@@H]1CC[C@H]4C[C@H](C1)OC(c2ccccc2)c3ccccc3;
	InChI InChI=1S/C22H27NO/c1-2-23-19-13-14-20(23)16-21(15-19)24-22(17-9-5-3-6-10-17)18-11-7-4-8-12-18/h3-12,19-22H,2,13-16H2,1H3/t19-,20+,21+ ; Key:PHTMLLGDZBZXMW-AERCQKQUSA-N ;
(what is this?) (verify);

エチベンザトロピン

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2013/12/05 23:49:41」(JST)

wiki en

[Wiki en表示]

Etybenzatropine (INN), also known as ethybenztropine (USAN, BAN) and tropethydrylin, is an anticholinergic/antihistamine marketed under the trade names Panolid, Ponalid, and Ponalide, which is used as an antiparkinsonian agent. Like its analogue benzatropine, it may act as a dopamine reuptake inhibitor.^{[citation needed]}

References[edit]

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

English Journal

Effects of etybenzatropine and diazepam on levodopa-induced diphasic dyskinesias in Parkinson's disease.

Pourcher E1, Bonnet AM, Kefalos J, Dubois B, Agid Y.Author information 1Clinique de Neurologie et Neuropsychologie, Paris, France.AbstractLevodopa-induced onset and end-of-dose dyskinesia are rare but disabling disorders. Although they can be attenuated by increasing and dividing the daily dose of levodopa, this does not constitute a therapeutic approach. In this pilot study, etybenzatropine, an anticholinergic drug, and diazepam, a selective benzodiazepine, were administered in addition to a single dose of levodopa in nine patients with Parkinson's disease. Both drugs tended to decrease the severity and the duration of onset and end-of-dose dyskinesia and to increase the duration of action of levodopa on parkinsonian symptoms.
Movement disorders : official journal of the Movement Disorder Society.Mov Disord.1989;4(3):195-201.
Levodopa-induced onset and end-of-dose dyskinesia are rare but disabling disorders. Although they can be attenuated by increasing and dividing the daily dose of levodopa, this does not constitute a therapeutic approach. In this pilot study, etybenzatropine, an anticholinergic drug, and diazepam, a s
PMID 2779590

Beneficial effects of dantrolene in the treatment of neuroleptic malignant syndrome: a report of two cases.

Goulon M, de Rohan-Chabot P, Elkharrat D, Gajdos P, Bismuth C, Conso F.AbstractTwo schizophrenic patients developed muscular rigidity, stupor, and hyperpyrexia consistent with neuroleptic malignant syndrome, 8 to 10 days after starting haloperidol therapy. Muscle rigidity was not affected by etybenzatropine or diazepam, but dantrolene, a direct-acting skeletal muscle relaxant, provided muscle relaxation with a concomitant decrease of fever and serum creatine kinase. Neuroleptic malignant syndrome and malignant hyperthermia are clinically similar, and dantrolene is effective in both; suggesting a muscular origin of fever in these two diseases.
Neurology.Neurology.1983 Apr;33(4):516-8.
Two schizophrenic patients developed muscular rigidity, stupor, and hyperpyrexia consistent with neuroleptic malignant syndrome, 8 to 10 days after starting haloperidol therapy. Muscle rigidity was not affected by etybenzatropine or diazepam, but dantrolene, a direct-acting skeletal muscle relaxant,
PMID 6682201